APPLICATIONS PUBLISHED 2 JUNE 2004
Published: 1-Dec-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Methods for treating genetically-defined proliferative disorders with HSP90 inhibitors
Conforma Therapeutic Corp 1423080*
Compsn comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints
Depuy International 1423081*
Plasma protein matrices and methods for their preparation
ProChon Biotech 1423082*
Stabilisation of oxidation-sensitive and UV-sensitive active ingredients
Beiersdorf 1423083*
Cosmetic oil-in-water preparation and use thereof for light skincare
Beiersdorf 1423084*
Oral compsn
Unilever 1423085*
Sensitive and rapid detection of pathogenic organisms and toxins using fluorescent polymeric ligands
The Regents of the University of California 1423091*
Functional powders for oral delivery
Vectura 1423092*
Bifunctional-modified hydrogels
Wisconsin Alumni Research Foundation 1423093*
A new method
AstraZeneca 1423094*
Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
Tel Aviv University Future Technology Development 1423095*
A process for preparing crystalline drug particles by means of precipitation
Dow Global Technologies 1423096*
Controlled release formulation of clarithromycin or tinidazol
Ranbaxy Laboratory 1423097*
A new extended release oral dosage form
AstraZeneca 1423098*
A new extended release oral dosage form
AstraZeneca 1423099*
Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
Trommsdorff 1423100*
Plaster for the treatment of dysfunctions and disorders of nails
Trommsdorff 1423101*
Plaster for the treatment of dysfunctions and disorders of nail growth
Trommsdorff 1423102*
Compsns and methods for modulation of DARPP-32 phosphorylation
The Rockefeller University 1423103*
Combination therapy for the treatment of neurological disorders
Eli Lilly 1423104*
Combinations of DMXAA and other anticancer agents
Cancer Research Technology 1423105*
Arylsulphonyl derivatives with 5-HT 6 receptor affinity
F Hoffmann-La Roche 1423106*
Fatty alcohol drug conjugates
Protarga 1423107*
C-2' methylated derivatives of paclitaxel for use as antitumour agents
Indena 1423108*
Compsns comprising pectin and ascorbic acid
DSM 1423109*
CBI analogues of CC-1065 and the duocarmycins
The Scripps Research Institute 1423110*
FXR NR1H4 nuclear receptor binding compounds
LION bioscience 1423111*
A combination of quetiapine and zolmetriptan
AstraZeneca 1423112*
NR1H4 nuclear receptor binding compounds
LION bioscience 1423113*
Method and compsns for treating migraines
Merck & Co 1423114*
Synthesis and anti-tumour activity of nitrogen-substituted thalidomide analogues
The Children's Medical Centre Corp; EntreMed 1423115*
Method of treating alcoholism or alcohol abuse
Biotie Therapies 1423116*
2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
Glaxo Group 1423117*
Method and compsn for treatment of cancer
Unisearch 1423118*
Heterobicycles FKBP-ligands
Agouron Pharmaceuticals 1423119*
2H-phthalazin-1-ones and methods for use thereof
Icos Corp 1423120*
Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other disease
Novartis 1423121*
Compsns and methods relating to novel benzodiazepine compounds and targets thereof
The Regents of the University of Michigan 1423122*
Tetracyclic indole derivatives as 5-HT receptor ligands
Pharmacia & Upjohn 1423123*
Lyophilised formulation comprising olanzapine
Eli Lilly 1423124*
Use of non-feminising oestrogens as retinoprotective agents for the treatment of glaucoma
Alcon 1423125*
Treatment of hyperproliferative conditions of body surfaces
Valderm 1423126*
Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
Ortho-McNeil Pharmaceutical 1423127*
Methods for the treatment of chronic pain and compsns therefor
Novartis 1423128*
Therapeutic process for P Aeruginosa infections using macrolide antibiotics
Anbics Patents-Licences 1423129*
Antithrombitic compsns comprising low molecular weight heparin and low molecular weight dermatin sulphate
Leo Pharma 1423130*
Calcium salts with cytotoxic activity
Bilton Consultadoria e Marketing 1423131*
Complex mixtures exhibiting selective inhibitions of cyclooxygenase-2
Metaproteomics 1423132*
Treatment of muscular dystrophies and related disorders
Brown University Research Foundation 1423133*
Human secreted proteins
Human Genome Sciences 1423134*
Methods for inhibiting angiogenesis
The Regents of the University of California 1423135*
Polypeptide conjugates with extended circulating half-lives
Epix Medical 1423136*
Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
Cubist Pharmaceuticals 1423137*
Use of IL-8 inhibitors in hypersensitivity disorders
Applied Research Systems 1423138*
New use of artemin, a member of the GDNF ligand family
Genentech 1423139*
Compsns and methods for modulation of immune responses
Soederstroem, Karl Petter 1423140*
Vaccine
Massey University 1423141*
Helicobacter pylori vaccination with a combination of CAGA, VACA and NAP proteins
Chiron 1423142*
Crystal forms and mutants of rank ligand
Barnes-Jewish Hospital 1423143*
Methods and compounds for disruption of CD40R/CD40L signalling in the treatment of Alzheimer's disease
University of South Florida 1423144*
Compsns for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
Aventis Pharma 1423145*
Compsn for treating Parkinson's disease containing a CB1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
Aventis Pharma 1423146*
Prostaglandin compsns and methods of treatment of male erectile dysfunction
Nexmed Holdings 1423147*
Cosmetic and dermatological light-protective formulation with content of water-soluble UV-filter
Beiersdorf 1423148*
Stabilisation of UV-sensitive active ingredients
Beiersdorf 1423149*
Sustained release of microcrystalline peptide suspensions
Zentaris 1423150*
Light-stabilised in vivo stain compsn and method of manufacture
Zila 1423151*
Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
Bristol-Myers Squibb Pharma 1423152*
Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointments
Healthpoint 1423154*
